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Abstract
Background: Macular oedema (MO) describes the accumulation of fluid in the central part of the retina, known as
the ‘macula’ which provides central vision. MO is the leading cause of sight loss in patients with intraocular
inflammation (uveitis). There is a lack of consensus over the treatment of uveitic macular oedema (UMO). The
proposed systematic review will evaluate the evidence on the effectiveness of pharmacological agents used to treat
UMO. All systemic, local, or topical pharmacological agents will be included.
Method/design: Standard systematic review methodology will be employed to identify, select and extract data
from comparative studies (randomised/non-randomised trials and observational studies) of the pharmacological
interventions in patients with UMO. Searches will be conducted through bibliographic databases (Cochrane Library,
MEDLINE, EMBASE and CINAHL) and clinical trials registers. No restriction will be placed on either language or year
of publication. Translation of non-English language articles will be undertaken to minimise selection bias. The
primary outcome of interest will be best corrected visual acuity and secondary outcomes will be adverse events,
health-related quality of life, assessment of UMO using central macular thickness (e.g. by optical coherence
topography (OCT)), clinical and angiographic assessment of UMO, clinical estimation of vitreous haze. Risk of bias
assessment appropriate to each study design will be undertaken. Data will be grouped by comparison, tabulated
and narratively synthesised. Meta-analysis will be undertaken where clinical and methodological homogeneity
exists. Subgroup and sensitivity analyses, also network analyses and intra/inter-pharmacological class analyses will
be undertaken where deemed appropriate.
Discussion: A number of published studies have investigated the effectiveness of the pharmacological agents used
to treat UMO. However, there is no recent systematic review that synthesises this evidence. This systematic review
will analyse the effectiveness of systemic, local and topical therapies to treat UMO. The findings will provide
important evidence to inform clinical and health policy decision-making for the treatment of UMO.
Systematic review registration: Prospero CRD42015019170
Keywords: Systematic review, Macular oedema, Macular edema, Uveitis, Management, Pharmacological agents,
Meta-analysis
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Background
Uveitis describes a group of disorders characterised by
intraocular inflammation. Uveitis is the fifth commonest
cause of visual loss in the developed world and accounts
for about 10–15 % of total blindness [1, 2] and up to
25 % in the developing world [3, 4]. Although uveitis
may affect any age group, it peaks in the working age
population with no significant gender difference [5]. The
annual incidence of uveitis is estimated at 14–50 per
100,000 with a prevalence of around 38–200 per 100,000
general population [1, 2, 5, 6].
Uveitis has a disproportionately high impact in terms
of years of potential vision loss and economic effects be-
cause it often strikes at a younger age than common
age-related eye disorders such as cataract, age-related
macular degeneration and glaucoma [1].
Uveitis may be classified anatomically as anterior uve-
itis, intermediate uveitis, posterior uveitis or panuveitis
[7, 8]. The leading cause of sight loss in patients with
uveitis is macular oedema and known in this context as
uveitic macular oedema (UMO) [1, 9]. Macular oedema
(MO) describes the accumulation of fluid in the retina
(the light-sensitive inner-lining of the eye) in the area
that provides central vision known as the ‘macula’ [10].
MO is more common in those forms of uveitis which
affect the more posterior structures in the eye, namely
intermediate, posterior or panuveitis; collectively, these
are sometimes referred to as posterior segment-
involving uveitis. MO can also occur in association with
anterior uveitis [11].
Macular oedema accounts for 41 % of visual impair-
ment and 29 % of blindness in uveitis [6, 12]. In the
Multicentre Uveitis Steroid Treatment (MUST) trial of
systemic corticosteroid vs a fluocinolone acetonide im-
plant in non-infectious intermediate, posterior and
panuveitis, it was noted that low vision (best corrected
visual acuity (BCVA) worse than 20/40) was present in
50 % of recruited patients and legal blindness (BCVA of
20/200 or worse) in 16 %, with cystoid macular oedema
being present in 38 % of eyes with similar distribution
across intermediate uveitis, posterior uveitis and panu-
veitis [13].
The impact of UMO on visual acuity is usually
assessed using standard distance visual acuity charts, ei-
ther using a Snellen chart or Early Treatment Diabetic
Retinopathy Study (ETDRS) chart. Acuities from Snellen
charts are usually reported in metres in the UK and feet
in the USA. Acuities from ETDRS charts are usually re-
ported either as ‘number of letters read’ or converted
into a LogMAR fraction. Although certain visual acuities
are considered to be equivalent (e.g. 0.0 LogMAR = 6/6
UK Snellen = 20/20 US Snellen), due to intrinsic differ-
ences between the charts, it is recognised that these
equivalences are approximate [11]. Although the Snellen
chart is still widely used in clinical practice, most trials
use ETDRS charts due to various methodological advan-
tages. Traditionally, MO has been assessed clinically
using stereoscopic slit-lamp fundus bio-microscopy and
fluorescein angiography, an invasive procedure requiring
intravenous dye and stereo photography imaging testing
[14]. More recently, a non-invasive imaging technique,
optical coherence tomography (OCT), has become a
standard clinical practice in the follow-up of UMO and
monitoring treatment response [15, 16]. OCT may be
more sensitive than clinical measures in detecting the
presence of UMO and provides accurate measures of the
structural changes in terms of macular thickness [17].
The treatment of UMO is a major priority in tackling
sight loss in uveitis and will be the focus of this study.
Corticosteroids are the mainstay of treatment for UMO
[10], with alternative routes of administration: systemic
(oral, intravenous and intramuscular); local which in-
cludes peri-ocular injection (sub-Tenon and orbital floor
injection) and intraocular (intra-vitreal injection or im-
plant) [18, 19]. ‘Second line’ therapies are typically im-
munomodulatory and include T cell inhibitors (e.g.
ciclosporine, tacrolimus), antimetabolites (e.g. azathio-
prine, methotrexate, mycophenolate Mofetil), alkylating
agents (e.g. cyclophosphamide) and biological agents
(e.g. interferons, antitumor necrosis factor (anti-tumour
necrosis factor (TNF)) agents) [20–23]. Most of these
agents are only used systemically (oral, intravenous or
subcutaneous), while intra-vitreal use has been reported
for both methotrexate and anti-TNF agents [22–25].
Other treatments that have been used in UMO include
the oral carbonic anhydrase inhibitor (acetazolamide),
and intra-vitreal anti-vascular endothelial growth factor
(anti-VEGF) agents [10, 26].
Whilst there have been narrative reviews on the
management of UMO, [10] a scoping search of
Cochrane library, MEDLINE, identified that only one
systematic review has been undertaken [16]. That re-
view aimed to cover all pharmacological interventions
for UMO and had fairly comprehensive searches, not
restricted by language or year of publication, under-
taken up to late 2011. The review only included RCTs
of which nine were reviewed. Limitations to this work
include a lack of steps to minimise bias in the review
process, and there are potential concerns over trans-
parency in reporting as the review does not meet
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-analyses standards). The review
highlights the availability of trials across the classes of
pharmacological interventions yet meta-analysis was
limited by heterogeneity and availability of data. The
authors also noted that relevant work was ongoing,
with more than 10 clinical trials related to UMO in
progress at the time of that review.
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Further, scoping work has suggested a role for non-
RCT evidence in this field. Scoping searches suggest that
RCTS in this field are likely to be small in size and may
have shorter periods of follow-up than non-RCTs. Non-
RCTs may therefore be more suitable for the detection
of adverse events. There is thus value in including the
non-RCT body of evidence in any new systematic
review.
Although there is a wide range of treatment options
available for UMO, there are currently no consensus
guidelines to direct treatment in this field. This may lead
to uncertainty for patients, clinicians and healthcare pro-
viders. It is timely to review the literature in order to
evaluate and summarise the available evidence for the
pharmacological agents used for the treatment of UMO,
which may form the basis of evidence-based clinical rec-
ommendations. Identifying the most effective treatment
for ocular inflammatory disease is the number one prior-
ity for research in inflammatory eye disease [27].
Methods/design
Aim
The aim is to assess the effectiveness of the available
pharmacological therapies used in the treatment of
UMO. The aim will be achieved by conducting a system-
atic review of studies:
 Comparing a pharmacological agent to the non-use
of a pharmacological agent.
 Comparing a pharmacological agent to the same or
another pharmacological agent.
Standard protocol-driven systematic review methods
will be used.
The systematic review protocol has been registered
with the international prospective register of systematic
reviews (PROSPERO) database ref (CRD42015019170)
and has been reported according to the PRISMA-P gui-
dlines (see Additional file 1).
Searches
The following sources will be searched.
 Bibliographic databases of published studies
 MEDLINE, MEDLINE in process (Ovid).
 EMBASE (Ovid).
 CINAHL (EBSCO)
 The Cochrane Library (CENTRAL Register of
Controlled Trials, Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects
and Health Technology Assessment database).
The search strategy will combine index and free text
terms for the condition (MO) and the disease context
(uveitis) where possible. A sample research strategy from
MEDLINE is provided in Table 1, and this strategy will
be adapted for the use in each bibliographic database.
Identified systematic reviews will be used to check if
all relevant primary studies are identified.
 Registers of Clinical trials
 Clinicaltrials.gov. www.clinicaltrials.gov.
 International Standard Randomised Controlled
Trials Number (ISRCTN database). www.contolled-
trials.com
 WHO International Clinical Trials Registry Platform
(ICTRP portal). www.who.int/ictrp/en/.
 UK Clinical Research Network (UKCRN).
www.ukcrc.org
 Abstract and conference proceedings
 British Library’s ZETOC.
 Conference proceedings Citation Index (Web of
Science).
 Dissertations, theses
 British library Ethos
 ProQuest. www.proquest.com
 Grey literature
 OpenGrey. www.opengrey.eu
These sources will be searched in a more iterative way
as complex search strategies may not be able to be used;
therefore, keywords/phrases based on macular edema/
oedema and uveitis will be employed.
There will be no restriction placed on either lan-
guage or year of publication; however, for conference
abstracts, only those within 3 years of the search date
will be considered. The literature search results will
be entered onto EndNote ×7 (Thomson Reuters) to
facilitate the removal of duplicate records, study se-
lection, recording decisions and references.
Selection criteria
The following criteria will be used to select studies for
review:
Table 1 MEDLINE sample search strategy for uveitic macular
edema
Count Searches
1 Exp Macular Edema/
2 (macular adj2 edema). ti,ab.
3 (macular adj2 edema). ti,ab.
4 1 or 2 or 3
5 Exp Uveitis/
6 Uveit$.ti,ab.
7 5 or 6
8 4 and 7
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 Study design
 Randomised controlled trials (RCTs) and other
comparative studies where the comparator group is
from a concurrent time period (e.g. non-randomised
controlled trials, comparative observational studies).
 Participants
 Participants of any age, gender or ethnicity with a
diagnosis of UMO.
Studies on a population broader than UMO will only
be included if data specific for the UMO subgroup is re-
ported separately.
 Intervention and comparator
 Comparing any pharmacological agent to no use of
a pharmacological agent.
 Comparing any pharmacological agent to the same
or another pharmacological agent.
 Outcomes
 Outcomes will not be used for study selection.
However, clinical- and patient-reported outcomes
are considered important for the aims of the review.
 Primary outcome.
 Best corrected visual acuity.
 Secondary outcome
 Adverse events.
 Health-related quality of life.
 Central macular thickness (e.g. by OCT)
 Angiographic assessment of UMO
 Clinical assessment of UMO
 Clinical estimation of vitreous haze
 Clinical estimation of anterior chamber cells
Selection process
The study selection process will be conducted in two
stages:
 First, title and abstract of the identified articles will
be screened in order to remove irrelevant records.
Articles that obviously do not meet the selection
criteria will be excluded.
 Second, the full text of the potential relevant articles
will be retrieved and assessed against all the
selection criteria.
At both stages, two reviewers will independently assess
articles with any disagreements resolved by discussion
and, if required, referral to a third reviewer. Both stages of
the selection process will be piloted and if necessary modi-
fied. The study selection processes will be illustrated using
a PRISMA flow diagram and details of articles excluded at
the full text stage will be recorded along with the reason
for exclusion [28].
Translation in part or wholly of non-English language
articles will be undertaken to aid study selection and
analysis.
Data extraction
Two authors will independently extract data from the in-
cluded publications. Any discrepancies will be resolved
through discussion and referral to a third reviewer if
needed. A standardised piloted data extraction form will
be used. Study authors may be contacted if further infor-
mation is required. For each study, the following infor-
mation (but not limited to) will be extracted.
 Study characteristics
 Authors—publication year—title and journal
 Study design
 Setting
 Sample size
 Length of follow-up
 Analysis
 Participant characteristics
 Patient selection/recruitment criteria
 Patients’ characteristics (demographic data, number,
age, gender, socioeconomic status and ethnicity).
 Type of uveitis (anatomical categorisation,
syndrome/aetiological classification)
 Comorbidity
 Co-medication
 Intervention and comparator
 Pharmacological agents
 Regimen (dose, frequency of administration, route of
administration)
 Comparator details
 Any difference in underlying care between treatment
groups
 Outcomes and findings
 Outcomes measured and results for each outcome
including precision and statistical test results.
 Completeness of follow-up for each outcome
Quality assessment
Quality assessment of all included articles will be under-
taken by two reviewers independently with disagree-
ments resolved by discussion and referral to a third
reviewer if required.
The risk of bias tool from the Cochrane Handbook
will be used for RCTs [29]. For non-randomised con-
trolled trials, the domains in the risk of bias tool for
RCTs will be used (accepting that criteria for randomisa-
tion and possibly concealment of allocation are not rele-
vant). For prospective controlled observational studies,
the guidelines outlined in Chapter 13 of the Cochrane
Handbook will be followed [29]. The domains in the risk
of bias tool for RCTs can be used as a minimum
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assessment (again accepting that the studies are not ran-
domised). The most relevant criteria for assessment in
this area are likely to relate to how the groups were se-
lected, differences in patient characteristics, loss to
follow-up and biases and confounding in outcome as-
sessment. Any case controlled studies/analyses will be
assessed based on the Newcastle-Ottawa scale [30].
Analysis
Studies will be grouped by each intervention and com-
parison, with data tabulated and a narrative synthesis of
evidence conducted for each outcome of relevance to
the review.
Assessment of clinical and methodological heterogen-
eity will be employed to determine whether for each
comparison for each outcome, studies are sufficiently
similar to ensure data pooling by meta-analysis is appro-
priate and whether a random effect or fixed effect model
is the most appropriate [31]. The I2 statistic (which gives
the percentage of the total variability in the data due to
between-study heterogeneity) and the tau-squared statis-
tic (which gives an estimate of the between-study vari-
ance) will be reported where appropriate. Data from
differing study designs will not be pooled together. For
each meta-analysis containing 10 or more studies, the
likelihood publication bias will be investigated and fun-
nel plot will be constructed [32].
It is expected that multiple time point data will be
available within the same study and between studies.
Nominally, data will be categorised in each analysis into
the following groups based on follow-up period:
≤3 months, >3 and ≤6 months and >6 months post in-
terventions. Within the last category, further division
may be considered to assess longer-term data.
Results for some outcomes are likely to be presented
using a number of different measure/statistics within the
same study and/or between studies. For example, visual
acuity may be reported in metres or feet (from Snellen
charts), a LogMAR score, number of letters or lines read
(from ETDRS charts), and the change in acuity may be
reported as a change in any one of these indices or cate-
gorised against a threshold, e.g. proportion of subjects
with change greater or equal to a specific number of
lines/letters read [11]. Visual acuity can therefore be
considered as continuous data (e.g. group mean Log-
MAR score), some as discrete data (e.g. number of lines
read) and some as dichotomous data (e.g. proportion of
patients reading x lines, or proportion with a LogMAR
score greater than y). The first and last are likely to be
the most common data. Conversion of data between for-
mats to maximise the data available for each analyses
will be considered (for example if the type of chart is
known, letters might be able to be converted to lines;
LogMAR score and letters interchanged; Snellen UK, US
and ETDRS data approximated. Any conversion of data
will be undertaken with due caution and with regard
known issues [11]. The impact of any converted data on
findings will be explicitly acknowledged.
Continuous data (e.g. health related quality of life)
from the same scale will be pooled using mean differ-
ence and from a different scale where tools are consid-
ered to be assessing the same underlying features,
standardised mean difference will be used. Further, sub-
group analysis will be considered where deemed appro-
priate. Where data allows, such analysis could include
grouping by clinical and anatomical classification to the
type of uveitis (anterior, intermediate, posterior and pan)
and route of administration of the intervention.
Direct comparison of interventions will be undertaken
via included head-to-head studies where these are avail-
able. For included randomised controlled trials, the po-
tential for network meta-analysis or adjusted indirect
comparison will be explored. It may be possible to esti-
mate the relative effect of the different pharmacological
agents if sufficient studies exist to inform the network.
The ability to undertake network meta-analyses/adjusted
indirect treatment comparisons will be dependent on a
number of key assumptions (e.g. the homogeneity, simi-
larity and consistency assumptions) [33, 34].
Based on all the above, as the interventions fall into
five classes of agent (corticosteroids, T cell inhibitors,
antimetabolites, alkylating agents and biological agents)
evidence of effect of agents within each class will be dis-
cussed to report on the consistency and magnitude of
the class effect. Finally, any inference of comparisons be-
tween classes will be considered.
Reporting
The review and its findings will be reported in accord-
ance to the PRISMA guidelines [28]. The strengths and
weaknesses of the review methods and the available evi-
dence will be discussed in relation to the internal and
external validity of the findings. The implications of the
review findings will be discussed in the context of
current and future clinical practice related to UMO and
the future research agenda.
Discussion and potential impact
UMO is a major cause of blindness in the working age
population. However, there is a wide variation in treat-
ment reflecting limitations in primary data and a lack of
national guidelines or consensus statements. This review
will systematically and comprehensively retrieve evi-
dence from a wide range of sources to evaluate the
pharmacological treatment of the UMO. Furthermore,
this review will provide valuable information regarding
the effectiveness of pharmacological agents.
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We hope this review will provide a clear reference
point for ophthalmologist and decision makers. The re-
vealed evidence will aid standardisation of clinical prac-
tice on the most effective therapies to improve outcomes
for patients and help minimise harm from inappropriate
therapies. Furthermore, this review is timely due to the
recent availability of novel local therapies which have
been approved by UK National Institute for Health and
Care Excellence (NICE) for other forms of MO, but
whose role in UMO is not yet established.
Additional file
Additional file 1. PRISMA-P 2015 checklist: recommended items to
include in a systematic review protocol.a (PDF 153 kb)
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